Albuterol off-label use in the management of hyperkalemia and students survey
Clinical and Administrative Pharmacy Sciences, College of Pharmacy, 2300 4th Street, NW, Washington, DC 20059.
Review
International Journal of Scholarly Research in Biology and Pharmacy, 2024, 04(02), 060–066.
Article DOI: 10.56781/ijsrbp.2024.4.2.0226
Publication history:
Received on 16 May 2024; revised on 22 June 2024; accepted on 25 June 2024
Abstract:
This study aimed to explore the evidence in the off-label use of albuterol in the acute management of hyperkalemia. It also aims to explore the knowledge and opinion of first-year pharmacy students related to this topic. Based on the literature survey, it shows a lack of awareness among first-year pharmacy students regarding albuterol, hyperkalemia, and the use of albuterol for hyperkalemia. Demographic factors, such as income and years of work experience, were shown to influence students' understanding of the topic. Regarding the survey, a total of forty participants completed an online survey, providing information on demographic factors such as age, gender, residency state, employment status, income, education, and work experience. Results revealed a predominantly female and younger student population, with diverse geographic representation and varied employment and income levels. Most participants selected the wrong answer to questions related to albuterol and hyperkalemia, suggesting potential knowledge gaps in this area. These findings highlight the need for targeted educational interventions to enhance student understanding and clinical decision-making skills in pharmacotherapy-related concepts. Further research could evaluate the effectiveness of such interventions in improving student knowledge and patient care outcomes.
Keywords:
Albuterol; Hyperkalemia; Survey; Pharmacy; Students
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0